BeiGene In-Licenses TNF-based Immunotherapy in $126 Million Agreement

Beijing's BeiGene in-licensed greater China rights to novel tumor necrosis factor receptor 2 (TNFR2) antagonist antibodies from Boston Immune Technologies and Therapeutics (BITT) in an agreement worth up to $126 million. TNFR2 is selectively expressed on many tumor types and also on suppressive immune cells in the tumor microenvironment. BeiGene plans to test BITR2101, BITT’s lead TNFR2 antagonist antibody, as a single agent and in combination with tislelizumab, the company’s anti-PD-1 antibody. More details.... Stock Symbol: (NSDQ: BGNE; HK: 06160) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.